> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# An oral KRAS G12D inhibitor shrank tumours in a third of treated pancreatic cancers
- URL: https://www.coios.me/an-oral-kras-g12d-inhibitor-shrank-tumours-in-a-third-of/
- Published: 2026-09-17T09:22:55.000Z
- Updated: 2026-09-17T09:22:55.000Z
- Description: In a phase 1 trial of 74 heavily pretreated patients with KRAS G12D-mutant advanced solid tumours, the oral inhibitor GFH375 produced confirmed responses in 35.1% of pancreatic cancers and 35.7% of non-small cell lung cancers, with median overall survival of 9.9 and 13.4 months respectively.
- Author: Daniel Ryan
- Tags: Healthcare today, Cancer, New medicines, China, #peer-reviewed, #new, #item, #source-2026-09

GFH375, an oral inhibitor targeting both the GTP- and GDP-bound states of KRAS G12D, was tested in a phase 1 dose-escalation and expansion trial in 74 patients with advanced solid tumours carrying the mutation, most with pancreatic ductal adenocarcinoma. The confirmed objective response rate was 35.1% (13/37) in pancreatic cancer, with median progression-free survival of 5.5 months and median overall survival of 9.9 months; in non-small cell lung cancer the response rate was 35.7%. Grade 3 or worse treatment-related adverse events occurred in 36.5% of patients, with one treatment-related death from septic shock.

*Why it is interesting: KRAS G12D is the commonest RAS mutation and long considered undruggable; a single-agent response rate above 30% in previously treated pancreatic cancer is the first signal of that changing.*

Source

[Nature medicine, 2026-09-15](https://doi.org/10.1038/s41591-026-04559-4?ref=coios.me)

DOI

10.1038/s41591-026-04559-4

Type

Peer-reviewed article

Design

Phase 1 dose-escalation and expansion trial, 74 heavily pretreated patients with KRAS G12D-mutant advanced solid tumours (43 pancreatic, 16 lung, 10 colorectal)

Verdict

New finding

Driver

[Cancer](https://www.coios.me/d-cancer/)

Driver

[New medicines](https://www.coios.me/d-new-medicines/)